Co.don AG - ESG Rating & Company Profile powered by AI
Complete Sustainability assessment of Co.don AG are reached by signing in. The analysis of Co.don AG employs information from across the web and also from available filings by Co.don AG. Jump to the end of this page for potential risks for Co.don AG based on sector, location and marketcap.
Co.don AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.1; made up of an environmental score of 2.7, social score of 1.6 and governance score of 8.0.
4.1
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
969 | Vertex Pharmaceuticals Inc | 4.2 | High |
969 | Zentalis Pharmaceuticals Inc | 4.2 | High |
989 | Co.don AG | 4.1 | High |
989 | Advanz Pharma Corp Ltd | 4.1 | High |
989 | Abeona Therapeutics Inc | 4.1 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Co.don AG have an accelerator or VC vehicle to help deliver innovation?
Does Co.don AG disclose current and historical energy intensity?
Does Co.don AG report the average age of the workforce?
Does Co.don AG reference operational or capital allocation in relation to climate change?
Does Co.don AG disclose its ethnicity pay gap?
Does Co.don AG disclose cybersecurity risks?
Does Co.don AG offer flexible work?
Does Co.don AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Co.don AG disclose the number of employees in R&D functions?
Does Co.don AG conduct supply chain audits?
Does Co.don AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Co.don AG conduct 360 degree staff reviews?
Does Co.don AG disclose the individual responsible for D&I?
Does Co.don AG disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Co.don AG disclose current and / or historical scope 2 emissions?
Does Co.don AG disclose water use targets?
Does Co.don AG have careers partnerships with academic institutions?
Did Co.don AG have a product recall in the last two years?
Does Co.don AG disclose incidents of discrimination?
Does Co.don AG allow for Work Councils/Collective Agreements to be formed?
Has Co.don AG issued a profit warning in the past 24 months?
Does Co.don AG disclose parental leave metrics?
Does Co.don AG disclose climate scenario or pathway analysis?
Does Co.don AG disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Co.don AG disclose the pay ratio of women to men?
Does Co.don AG support suppliers with sustainability related research and development?
Does Co.don AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Co.don AG reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Co.don AG involved in embryonic stem cell research?
Does Co.don AG disclose GHG and Air Emissions intensity?
Does Co.don AG disclose its waste policy?
Does Co.don AG report according to TCFD requirements?
Does Co.don AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Co.don AG disclose energy use targets?
Does Co.don AG disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Co.don AG have a policy relating to cyber security?
Have a different question?
Potential Risks for Co.don AG
These potential risks are based on the size, segment and geographies of the company.
co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.